Avantor (NYSE:AVTR) Given New $26.00 Price Target at Stifel Nicolaus

Avantor (NYSE:AVTR) had its target price decreased by Stifel Nicolaus from $28.00 to $26.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 35.77% from the company’s current price.

Other equities analysts have also issued research reports about the company. UBS Group restated a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company lowered their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Raymond James cut their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Barclays cut their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Monday. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.08.

Avantor Price Performance

Shares of AVTR stock opened at $19.15 on Monday. The company has a market capitalization of $13.03 billion, a P/E ratio of 41.63, a P/E/G ratio of 3.87 and a beta of 1.28. The company’s 50-day simple moving average is $21.73 and its two-hundred day simple moving average is $23.46. Avantor has a one year low of $19.08 and a one year high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the company earned $0.22 EPS. As a group, equities analysts anticipate that Avantor will post 0.98 EPS for the current year.

Institutional Investors Weigh In On Avantor

A number of large investors have recently modified their holdings of AVTR. MassMutual Private Wealth & Trust FSB raised its position in shares of Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after buying an additional 830 shares during the last quarter. UMB Bank n.a. acquired a new position in shares of Avantor in the 3rd quarter valued at $49,000. Global Retirement Partners LLC raised its stake in Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after acquiring an additional 1,067 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.